Philadelphia has long been a city of innovation. For the last 25 years, Integral Molecular has helped write that story, advancing better, safer antibody drugs and developing tools that accelerate vaccine discovery.
Founded and grown in Philadelphia, Integral Molecular develops and applies innovative technologies to study and target membrane proteins for therapeutics. These proteins include some of the most important and challenging disease targets. Sitting at the interface between cells and their environment, membrane proteins play central roles in cancer, autoimmune disease, infectious disease, and immune response. Alongside its scientific endeavors, Integral Molecular is a proud member of the Philadelphia community, actively engaging in service opportunities and helping to build a new generation of scientists.
Deeply Rooted in Philadelphia
Integral Molecular’s story begins at the University of Pennsylvania, where the company’s scientific founders—Drs. Ben Doranz, Joseph Rucker, and Sharon Willis—met while working as PhD students and post doctoral researchers. With a shared interest in virology and drug discovery, they laid the groundwork for a company that would later become a cornerstone of the city’s biotechnology hub.
Philadelphia’s academic and entrepreneurial ecosystem made it possible for Integral Molecular’s cofounders to transform their scientific ideas into a company. After developing a business plan that won the Wharton Business School Business Plan Competition and securing funding from the National Institutes of Health, Integral Molecular launched with just two people in an incubator laboratory at the University City Science Center.
The University City Science Center played a critical role in the company’s growth, providing access to shared infrastructure, lab space, and a community of fellow innovators. The incubator allowed Integral Molecular’s small team to focus on building its core technologies. From this modest beginning, the company has grown to more than 100 employees operating in a 50,000-square-foot, state-of-the-art laboratory and office facility in Philadelphia’s University City biotech hub.
Integral Molecular has also benefited from continued public support at both the city and state levels, including Philadelphia’s SBIR matching funds and Pennsylvania’s Redevelopment Assistance Capital Program (RACP). These investments reflect the region’s commitment to nurturing homegrown biotechnology companies and demonstrate how public funding can translate into lasting scientific and economic impact.
Integral Molecular At-a-Glance:
- Company founded in Philadelphia in 2001 with 2 original employees
- Headquartered in University City, Philadelphia, with over 100 employees
- Developed key innovations including Lipoparticles, the Membrane ProteomeArray™, and Reporter Virus Particles (RVPs), supporting better antibody drugs and accelerated vaccine research
- Technologies cited in 600+ publications and patents
- Recognized as an Employer of Choice by the City of Philadelphia and a Top Workplace by the Philadelphia Inquirer
- Provides solutions to over 600 biotechnology and pharmaceutical organizations worldwide
Making Better and Safer Antibody Drugs
Antibody drugs are therapeutics that resemble the body’s natural immune molecules. They make effective treatments because they are designed to precisely recognize and bind to specific target proteins, such as those found on viruses or cancer cells. Integral Molecular leads the industry in developing specialized technologies that enable the discovery and characterization of antibodies against some of the most challenging biological targets. The company applies its own internally developed technologies to discover therapeutic molecules, including CTIM-76, which is currently in clinical trials through a partnership with fellow Philadelphia company Context Therapeutics.
Integral Molecular is also the developer of the Membrane Proteome Array™, a platform that allows researchers to assess exactly which human proteins an antibody binds. This information is crucial for antibody drug developers because it lets them know before testing the drug in people if it is interacting with any proteins other than the intended target—highlighting possible safety liabilities. The Membrane Proteome Array™ is currently under review by the FDA with the potential to set a new standard for testing antibody therapeutics in a rapid, human-relevant system.
Today, more than 600 biotechnology and pharmaceutical companies worldwide use Integral Molecular’s technologies in their drug discovery pipelines, helping advance antibody therapies that are not only more effective, but also safer for patients.
Tools to Expedite Vaccine Development
Integral Molecular’s deep expertise in virology has been a defining feature of the company since its start. Building on this foundation, the company has developed tools that allow scientists to efficiently and safely measure how viruses infect cells and how drugs or vaccines can block this process. The company has invented tools including Reporter Virus Particles (RVPs) and Ready Reporter Viruses (RRVs) that enable researchers to safely conduct these studies without handling pathogenic viruses. These technologies have been widely adopted to support vaccine research and antibody development for viral threats including SARS-CoV-2, Ebola, Zika, and Dengue. By making virology research more accessible, Integral Molecular helps to accelerate vaccine development and strengthen global pandemic preparedness.
A Legacy of Community Engagement
Integral Molecular’s commitment to Philadelphia extends beyond its labs and technologies. For 25 years, the company has been deeply engaged with the local community, supporting educational programs that reach students from middle school through graduate school. Hands-on initiatives like eCLOSE and FirstHand, along with educational partnerships with institutions such as Drexel University and the Wistar Institute, help spark curiosity in science and open doors to careers in biotechnology.
At the same time, Integral Molecular plays a key role in retaining highly trained scientific talent in the region. Many team members come from Philadelphia-area universities and research institutions, strengthening the local life sciences workforce and reinforcing the city’s position as a leading biotech hub.
Looking Forward
As Integral Molecular celebrates its 25th anniversary alongside Philadelphia’s 250-year legacy of innovation, the company remains firmly committed to the city that enabled its growth. From a two-person lab in the Science Center incubator to a thriving organization supporting hundreds of drug and vaccine programs worldwide, Integral Molecular’s journey reflects the power of bold ideas, collaboration, and sustained investment in science.
